lopinavir
Selected indexed studies
- Lopinavir-ritonavir for COVID-19: A living systematic review. (Medwave, 2020) [PMID:32678815]
- Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. (J Pharm Pharm Sci, 2021) [PMID:34048671]
- Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. (Eur Rev Med Pharmacol Sci, 2020) [PMID:32894567]
_Worker-drafted node — pending editorial review._
Connections
lopinavir is a side effect of
Sources
- Lopinavir-ritonavir for COVID-19: A living systematic review. (2020) pubmed
- Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. (2021) pubmed
- Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. (2020) pubmed
- Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. (2021) pubmed
- Lopinavir. (2000) pubmed
- Kaletra (lopinavir/ritonavir). (2002) pubmed
- Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices. (2022) pubmed
- BET 1: Lopinavir-ritonavir and COVID-19. (2020) pubmed
- Lopinavir-Ritonavir: a new protease inhibitor. (2001) pubmed
- Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods. (2024) pubmed